title: Long-term safety of abatacept in patients with rheumatoid arthritis.
abstract: Abatacept is a selective T cell co-stimulation modulator that was first approved by the Italian Medicines Agency and reimbursed by the Italian National Health Service when used to treat active rheumatoid arthritis "not sufficiently responsive to other disease-modifying anti-rheumatic drugs (DMARDs) including at least one TNF inhibitor", and is now also approved as a first line biological agent. The aim of this review is to summarise the safety data collected in clinical trials and observational studies.
authors.affiliation: Rheumatology Unit, L. Sacco University Hospital, Milan, Italy.
authors.forename: Fabiola
authors.initials: F
authors.lastname: Atzeni
authors.forename: Piercarlo
authors.initials: P
authors.lastname: Sarzi-Puttini
authors.forename: Alessandra
authors.initials: A
authors.lastname: Mutti
authors.forename: Serena
authors.initials: S
authors.lastname: Bugatti
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Cavagna
authors.forename: Roberto
authors.initials: R
authors.lastname: Caporali
mesh_terms: D000069594:Abatacept; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects* / Q000627:therapeutic use; D064887:Observational Studies as Topic
chemical_list: D018501:Antirheumatic Agents; D018796:Immunoconjugates; D000069594:Abatacept
keywords: Abatacept; Rheumatoid arthritis; Safety